Ontology highlight
ABSTRACT:
SUBMITTER: Nakayama T
PROVIDER: S-EPMC3412494 | biostudies-literature | 2012 Aug
REPOSITORIES: biostudies-literature
Nakayama Tomoko T Butler James S JS Sehgal Alfica A Severgnini Mariano M Racie Tim T Sharman Jennifer J Ding Feng F Morskaya Svetlana Shulga SS Brodsky Joshua J Tchangov Lubomir L Kosovrasti Verbena V Meys Mike M Nechev Lubomir L Wang Gang G Peng Chang Geng CG Fang Yupang Y Maier Martin M Rajeev Kallanthottathil G KG Li Robert R Hettinger Julia J Barros Scott S Clausen Valerie V Zhang Xuemei X Wang Qianfan Q Hutabarat Renta R Dokholyan Nikolay V NV Wolfrum Christian C Manoharan Muthiah M Kotelianski Victor V Stoffel Markus M Sah Dinah Wy DW
Molecular therapy : the journal of the American Society of Gene Therapy 20120605 8
Therapeutics based on RNA interference (RNAi) have emerged as a potential new class of drugs for treating human disease by silencing the target messenger RNA (mRNA), thereby reducing levels of the corresponding pathogenic protein. The major challenge for RNAi therapeutics is the development of safe delivery vehicles for small interfering RNAs (siRNAs). We previously showed that cholesterol-conjugated siRNAs (chol-siRNA) associate with plasma lipoprotein particles and distribute primarily to the ...[more]